When a stock trades at 36 times trailing earnings, most value-oriented investors scroll right past it. But that headline multiple is exactly the trap that has kept many investors from understanding the setup in Humana (NYSE: HUM) today. The trailing P/E is high not because the stock is expensive, but because earnings are sitting in a deliberately engineered trough — and the entire investment case rests on a single question: can Humana rebuild its Medicare Advantage margins back toward a sustainable 3% pretax level by 2028?
In late July 2026, Humana reported second-quarter results that beat on the top and adjusted-earnings lines yet forced the company to cut its GAAP full-year outlook because of a Medicare Advantage Star Ratings headwind. The stock initially sold off. Then something unusual happened: within roughly a week, five separate Wall Street firms upgraded the stock or sharply raised their price targets. Morgan Stanley moved off its long-standing bearish stance, Piper Sandler and Evercore ISI pushed to their most positive ratings, and Guggenheim lifted its target to $471. The reason was not the quarter itself — it was growing conviction that the Humana Medicare Advantage margin recovery thesis is real, quantifiable, and mispriced.
This article makes the case that Humana is a classic “trough earnings” recovery play in a defensive, structurally growing industry. Three points anchor the thesis. First, the trailing P/E of 36x is meaningless — the right lens is normalized 2028 earnings power, where consensus is converging on roughly $28–30 in EPS versus $10.56 on a trailing basis, which reframes the stock at a low-double-digit forward multiple on recovered earnings. Second, Humana is the most Medicare-Advantage-concentrated of the large managed-care insurers, which cuts both ways — it magnified the recent pain but also gives it the most direct leverage to an MA margin recovery and the demographic tailwind of an aging U.S. population. Third, the CenterWell healthcare-services segment is quietly compounding at high-teens growth and heading toward $25 billion in annual revenue, giving Humana a second, less cyclical earnings engine that the market largely ignores in a sum-of-the-parts framework.
Over the following sections we will map Humana’s business model and segment economics, size the Medicare Advantage industry and its structural drivers, dissect the company’s economic moat, walk through the financials that explain the trough-and-recovery shape, build a valuation grounded in the authoritative figures fetched for this analysis, lay out the risks that could break the thesis, and finish with a concrete rating, entry range, and exit plan. The current price is $384.48, the analyst consensus target is $418.46, and the real debate is whether 2028 earnings power justifies something meaningfully higher.
—
1. Company Overview
Humana is one of the largest health insurers in the United States, but the label “health insurer” undersells how specialized the company has become. Unlike diversified peers that spread themselves across commercial group insurance, exchanges, and government programs, Humana has spent the last several years deliberately concentrating on government-sponsored healthcare for seniors — chiefly Medicare Advantage (MA), the privately administered alternative to traditional fee-for-service Medicare. As of June 30, 2026, Humana served approximately 17.9 million total members, of which roughly 7.2 million were enrolled in Medicare Advantage — a striking jump from about 5.8 million a year earlier.
How Humana makes money. The core model is capitated risk. For each Medicare Advantage member, Humana receives a fixed monthly payment from the Centers for Medicare & Medicaid Services (CMS), adjusted for the member’s health status (risk adjustment) and the quality of the plan (Star Ratings bonuses). Humana then pays for that member’s medical care out of those premiums. The gap between premiums collected and medical costs paid — expressed inversely as the medical loss ratio (MLR) — is the engine of profitability. In Q2 2026, Humana’s MLR was 91.1%, meaning roughly 91 cents of every premium dollar went straight back out as medical claims, leaving very little for administrative costs and profit. That figure was up from 89.7% a year earlier, and it is the single number that explains why earnings are depressed today.
Revenue breakdown by segment. Humana reports through two primary segments:
Segment What it is Approx. scale Growth profile Insurance Medicare Advantage, standalone PDP (drug plans), Medicaid, and specialty ~$140B+ annualized revenue High-teens membership growth in MA; margin-recovery story CenterWell Pharmacy dispensing, senior-focused primary care clinics, and home health Guided toward ≥$25B in 2026 revenue ~20% YoY revenue growth; less cyclical
The Insurance segment is by far the larger of the two and drives the near-term earnings volatility. CenterWell is the strategic offset: it is Humana’s vertically integrated care-delivery arm, spanning one of the largest senior-focused primary care platforms, a home-health business, and a specialty/mail pharmacy operation. In the first quarter of 2026, CenterWell generated about $6.1 billion in revenue, up 19.7% year over year across all three lines, and management expects the segment to clear $25 billion for the full year, aided by the integration of the MaxHealth clinic network.
Market position and customers. Humana’s “customer” is effectively twofold: the individual senior who chooses a Humana MA plan during annual enrollment, and CMS, which funds the vast majority of the premium. This gives the business unusual revenue visibility — payments are federal, recurring, and demographically underpinned — but also unusual regulatory sensitivity, since a single CMS rule change on rates or Star Ratings can swing profitability materially, as 2026 has demonstrated.
Ownership and governance. Humana is a widely held S&P 500 constituent with a market capitalization of approximately $46.2 billion and about 120.1 million shares outstanding. The register is dominated by large institutional index and active managers typical of a large-cap managed-care name; insider ownership is modest, consistent with a mature, professionally managed insurer. The balance sheet carries a debt-to-equity ratio of about 0.74 — moderate leverage appropriate for a regulated insurer that must hold statutory capital against its risk pools.
—
2. Industry Analysis
The Medicare Advantage industry sits at the intersection of two powerful forces: an irreversible demographic wave and a policy framework that channels an increasing share of federal healthcare spending through private insurers. Understanding this industry is essential, because Humana is arguably the purest large-cap bet on it.
2-1. Market Size & Growth Trajectory
Medicare covers Americans aged 65 and older plus certain younger people with disabilities. The total Medicare-eligible population has been expanding by roughly 10,000 people turning 65 every day as the Baby Boomer cohort ages, and that flow continues well into the 2030s. Within Medicare, the privately administered Medicare Advantage option has grown from a minority choice two decades ago to the majority of new Medicare enrollees, with well over half of all Medicare beneficiaries now enrolled in an MA plan rather than traditional fee-for-service.
In dollar terms, Medicare Advantage represents a market measured in the high hundreds of billions of dollars of annual premium flowing from CMS to private insurers, and it has compounded at a high-single-digit to low-double-digit annual rate over the past decade — a rare combination of scale and durable growth in a mature economy. The industry is not early-stage; MA penetration is now past the halfway mark of the eligible population. But it is not saturated either. The right way to characterize where the industry sits in its cycle is mid-to-late acceleration: penetration continues to climb toward the 60–70% range that many observers view as a plausible ceiling, the absolute number of eligible seniors keeps rising, and the per-member revenue base grows with medical inflation. That combination sustains volume growth even as the penetration rate matures.
Critically, 2026 is a “reset” year for the industry’s profitability, not its growth. After several years in which insurers priced plans too aggressively — offering rich benefits to win members while medical utilization rebounded faster than expected — the entire sector is in a repricing cycle. Utilization normalized higher (more elective procedures, higher-cost specialty drugs, sicker new enrollees), CMS tightened risk-adjustment methodology, and Star Ratings bonus dollars compressed. The result is an industry-wide margin trough in 2026, with every major MA insurer guiding to depressed profitability and then rebuilding through the 2027 and 2028 bid cycles. This is the backdrop against which Humana’s specific recovery must be judged: it is not fighting a secular decline, it is riding out a cyclical repricing in a growing market.
2-2. Structural Growth Drivers
Driver 1 — The demographic tailwind is non-negotiable. The single most reliable feature of this industry is that its addressable population grows regardless of the economy, interest rates, or market sentiment. Every year, millions of Americans age into Medicare eligibility, and a majority of them now select Medicare Advantage. For Humana, this means the top of the funnel refills automatically. Even in a “bad” year like 2026, Humana’s MA membership grew sharply year over year to roughly 7.2 million — the volume growth is real and durable. Over a five-to-ten-year horizon, the sheer arithmetic of the aging population underpins mid-to-high-single-digit membership growth for well-run MA plans, before any pricing or share gains. This is a structural, long-duration driver, not a cyclical one, and it is the foundation of the entire investment case.
Driver 2 — Vertical integration into care delivery. The industry’s second structural shift is the move from pure insurance toward owning the care itself. Insurers have learned that the most reliable way to control the medical loss ratio is to influence how, where, and how efficiently care is delivered — especially primary care for seniors, where proactive management of chronic conditions prevents expensive hospitalizations. Humana’s CenterWell segment is the embodiment of this strategy: senior-focused primary care clinics, home health, and pharmacy that together create a value-based care flywheel. When a member receives coordinated primary care through an owned clinic, medical costs are more predictable and often lower, which feeds back into better plan economics. This driver is both a growth engine (CenterWell revenue compounding near 20%) and a margin lever (better cost control in the Insurance segment). Over the long term, the integrated model is the industry’s answer to margin volatility, and Humana is further down this path than most peers relative to its size.
Driver 3 — Policy-anchored, inflation-linked revenue. Medicare Advantage premiums are set through an annual CMS “rate notice” and bid process, and they broadly track medical cost inflation over time. While a single year’s rate update can be a headwind (as risk-adjustment and Star Ratings changes have been recently), the multi-year trend is for CMS payments to rise with the cost of caring for an aging population. This gives the industry a built-in inflation hedge that most consumer-facing businesses lack: as medical costs rise, so, eventually, does the premium base. The near-term dynamics — where utilization outran pricing — are precisely what the 2027 and 2028 bid cycles are designed to correct, as insurers reprice benefits and trim unprofitable plans. In the short term this pressures membership growth and benefits; in the long term it restores the structural link between costs and revenue.
2-3. Competitive Landscape
Medicare Advantage is an oligopoly of large, well-capitalized insurers, each with a somewhat different strategic tilt. The table below frames the major players qualitatively; Humana’s distinguishing feature is its concentration.
Company MA positioning Diversification Strategic tilt UnitedHealth (UNH) The largest MA insurer by membership Highly diversified (Optum services, commercial, international) Scale + Optum vertical integration Humana (HUM) A leading MA-focused insurer Low — MA is the dominant book Purest MA + CenterWell care delivery CVS Health / Aetna (CVS) Large MA presence Diversified (retail pharmacy, PBM, Aetna) Integrated pharmacy + insurance Elevance Health (ELV) Significant MA plus large commercial/Blues franchise Diversified across commercial and government Blues brand + Carelon services Cigna (CI) Smaller direct MA; large PBM (Evernorth/Express Scripts) PBM-heavy Pharmacy services scale
Why is Humana better positioned than peers for this particular setup? Precisely because it is the least diversified. For a diversified insurer, an MA margin recovery is one positive among many moving parts, diluted by commercial and other lines. For Humana, an MA recovery flows almost directly to the bottom line — the concentration that hurt it most on the way down provides the most direct leverage on the way up. Layer on CenterWell, which gives Humana a care-delivery asset scaled to its senior membership, and the company offers investors the cleanest, highest-beta expression of the MA recovery thesis among large-cap managed care. The trade-off, addressed in the risk section, is that this same concentration removes the shock absorbers that diversified peers enjoy.
—
3. Economic Moat Analysis
Humana’s moat is real but nuanced. It is not the impregnable brand of a consumer-staples giant; it is a moat built from regulatory scale, switching inertia, and vertical integration in a business where operational execution and data compound over time.
Moat Type 1: Efficient Scale and Regulatory Complexity
Medicare Advantage is a business where scale is not a vanity metric — it is a structural cost and quality advantage. Running MA plans requires enormous fixed investment in actuarial pricing, provider-network contracting, risk-adjustment coding accuracy, regulatory compliance, and Star Ratings quality operations. These costs are largely fixed and spread across the membership base. Humana’s roughly 7.2 million MA members give it the density to negotiate favorable provider rates in its core geographies, to invest in the data infrastructure that improves risk-adjustment accuracy, and to fund the quality programs that drive Star Ratings. A subscale entrant cannot replicate this — the regulatory learning curve alone (navigating annual CMS rate notices, audit regimes, and bid mechanics) is a formidable barrier. This is classic efficient scale: the addressable market in any given county supports only a handful of profitable MA plans, and incumbents with density are extremely hard to dislodge.
The evidence is in the moat’s stickiness even through a bad year. Despite the 2026 Star Ratings setback and margin pressure, Humana still grew MA membership meaningfully and retained its position as one of the two or three insurers that seniors and brokers default to in most markets. Members do not casually switch away from a plan that has managed their chronic conditions and whose network includes their doctors — which brings us to the second moat.
Moat Type 2: Switching Costs and Care Integration
For a senior, changing Medicare Advantage plans is genuinely costly in non-monetary terms. It can mean changing primary care physicians, re-establishing prescription coverage, learning a new plan’s rules, and risking that a preferred specialist is out of network. This creates meaningful switching costs and high retention among established members — the reason MLR actually rose for Humana as it added new members is instructive: newer enrollees are higher-acuity and less understood than the multi-year members Humana retains, which tells you that the retained book is precisely the profitable, sticky core. As those newer members season and their care is brought into value-based arrangements, their economics improve.
CenterWell deepens these switching costs. When a Humana member also uses a CenterWell primary care clinic, a CenterWell home-health nurse, and CenterWell pharmacy, the relationship becomes an integrated care ecosystem rather than a swappable insurance product. That integration is hard for a competitor to replicate and hard for a member to leave. It also gives Humana proprietary clinical data that improves both care outcomes and cost prediction — a compounding information advantage that strengthens the more members flow through owned care settings.
Moat Durability Assessment
Will this moat hold over the next five to ten years? On balance, yes, but with a clear-eyed view of the erosion risks. The demographic and scale advantages are highly durable — the aging population is not reversing, and the regulatory complexity that protects incumbents is, if anything, increasing. The switching-cost and integration advantages should strengthen as CenterWell scales toward and beyond $25 billion in revenue and as value-based care deepens.
The genuine threats to the moat are twofold. First, regulatory: because CMS sets the rules and the rates, a sustained policy shift — tighter risk adjustment, lower benchmark growth, or a structural reduction in MA payment generosity — could compress the entire industry’s economics in a way no company-specific moat can fully offset. This is the defining risk of the business model and is addressed in Section 6. Second, Star Ratings execution: Humana’s 2026 pain was partly self-inflicted through a Star Ratings slip that cost it quality-bonus dollars. Star Ratings are within management’s operational control, so a rebound is achievable, but it must be executed year after year. A moat that depends on continued operational excellence in quality scoring is real but not automatic. The counterargument is that Humana has both the scale to invest in quality and every financial incentive to restore its ratings — and management has publicly made margin recovery, which is inseparable from Star Ratings, its top priority.
—
4. Financial Analysis
Humana’s financial picture only makes sense once you accept that 2026 is a deliberate earnings trough, not a steady state. The company is absorbing higher medical costs and reduced quality bonuses now, while repricing its book for 2027 and 2028.
Revenue and earnings trend. Revenue has compounded steadily as membership has grown, even as profitability has swung with the medical-cost cycle:
Metric FY2023 FY2024 FY2025 (approx.) TTM (mid-2026) Total revenue ~$106.4B ~$117.8B ~$126.9B $145.68B Net income ~$2.5B ~$1.2B ~$1.2B $1.28B
(TTM figures shown in bold are the authoritative fetched values; prior-year figures are drawn from company filings and rounded.)
The story the table tells is unambiguous: top-line growth has been relentless while net income has been cut roughly in half from its 2023 level and then held in a trough. Revenue rose about 26% year over year in the most recent quarter, driven by MA membership gains and medical-cost pass-through, yet net income has stagnated near $1.2–1.3 billion because rising medical costs and lower Star Ratings bonuses have compressed margins. That divergence between soaring revenue and flat profit is the trough — and it is exactly what a recovery is designed to unwind, as recovered margins are applied to a much larger revenue base.
Key operating metrics. For a managed-care insurer, the metrics that matter most are membership, MLR, and segment revenue:
– Medicare Advantage membership: roughly 7.2 million as of June 30, 2026, up from about 5.8 million a year earlier — strong volume growth despite the margin reset.
– Medical loss ratio: 91.1% in Q2 2026 (up from 89.7% a year earlier); first-half MLR of 90.2% versus 88.4% in the prior-year first half. Every point of MLR improvement is worth an enormous amount of operating profit on a $140-billion-plus premium base — which is the mechanical core of the recovery thesis.
– CenterWell revenue: about $6.1 billion in Q1 2026, up 19.7% year over year, guided toward $25 billion-plus for the full year.
Profitability and returns. On a trailing basis, Humana’s operating margin sits around 1.86% and net profit margin around 0.88%, with return on equity of about 6.83% and return on assets of about 2.38%. These are trough-level returns for a business that historically earned mid-teens ROE — and that gap between trough and normalized returns is the opportunity. The company’s stated target is a sustainable pretax margin of at least 3% in Medicare Advantage by 2028, with individual MA margins moving from below breakeven in 2026 toward roughly 2.5% in 2028. On a $140-billion-plus revenue base, restoring even a couple hundred basis points of margin translates into a multi-billion-dollar swing in pretax profit.
Balance sheet. Humana carries a debt-to-equity ratio of about 0.74 — moderate for a regulated insurer that must hold statutory reserves. The company generates substantial operating cash flow from premium float, and its price-to-book of 2.40 reflects a business earning below its normalized return on equity today. There is no solvency question here; the issue is purely earnings power, not balance-sheet health.
The margin-expansion story. Unlike a pre-profit growth company that must prove it can ever make money, Humana has a long history of profitability and a clear, mechanical path back to it: reprice unprofitable plans in the 2027 bids, exit selected unprofitable markets, restore Star Ratings to recapture quality bonuses, and let CenterWell’s value-based care flywheel bend the cost curve. Each lever is identifiable and quantifiable, which is why analysts have grown comfortable modeling 2028 EPS in the high-$20s to low-$30s versus $10.56 on a trailing basis.
—
5. Valuation
Valuing Humana on its trailing P/E of 36.4x (price $384.48 ÷ trailing EPS $10.56) is analytically wrong, because trailing earnings are at a cyclical trough. The correct approach is to value the company on its normalized, recovered earnings power and cross-check against the forward multiple and analyst consensus.
Anchor figures (authoritative, as fetched):
Metric Value Current price $384.48 Market cap $46.17B Shares outstanding 120.08M EPS (trailing twelve months) $10.56 EPS next year (consensus) $16.72 Trailing P/E 36.4x Forward P/E 23.0x Price / book 2.40 Price / sales 0.32 52-week range $163.11 – $428.88 Analyst consensus target $418.46
Step 1 — Forward earnings check. On next year’s consensus EPS of $16.72, the stock trades at a forward P/E of 23.0x (384.48 ÷ 16.72 = 23.0). That is already a large step down from the trailing 36x, and it reflects the first year of margin recovery. But 2027 is only a waypoint — the thesis is about 2028.
Step 2 — Normalized 2028 earnings power. The 2028 bull case rests on Humana restoring MA margins toward its 3% pretax target while CenterWell keeps compounding. Analysts modeling this recovery have converged on 2028 EPS estimates in the high-$20s to low-$30s; Guggenheim, for instance, has published a 2028 EPS estimate around $30. For a conservative base case, we use 2028 EPS of $28 — below the most optimistic estimates to build in execution risk.
Step 3 — Apply a normalized multiple. Managed-care insurers with restored margins have historically traded in the mid-teens P/E range. Applying a 15x multiple to base-case 2028 EPS of $28 yields a value of roughly $420 — remarkably close to the current analyst consensus target of $418.46. This convergence is reassuring: two independent methods (Street consensus and a normalized-earnings build) land in the same neighborhood, suggesting $415–420 is a well-supported base-case fair value.
Step 4 — Scenario analysis.
Scenario 2028 EPS assumption Multiple Implied value Upside/downside vs $384.48 Bull $30.5 (full 3%+ MA margin, CenterWell ahead of plan) 16x ~$488 +27% Base $28.0 (margins recover near target, some plan attrition) 15x ~$420 +9% Bear $20.0 (Star Ratings/regulatory setback stalls recovery) 13x ~$260 −32%
Step 5 — Reconcile with consensus. The analyst consensus target of $418.46 sits almost exactly on our base case, implying roughly 9% upside from the current price plus whatever dividend the shares pay. We broadly agree with consensus on the base case but see more asymmetry than the single point target suggests: the bull case (+27%) is a credible outcome if the 2028 margin target is fully achieved, while the bear case (−32%) is a genuine risk if the recovery stalls. The reason five analysts upgraded in a single week is that the Q2 print, despite the GAAP guidance cut, did nothing to break the 2028 recovery math — it simply confirmed that 2026 is the trough. On a risk-adjusted basis, an investor buying near $384 is paying a fair price for the base case and getting the bull-case optionality for free, provided they can tolerate the bear-case downside.
—
6. Risk Factors
Risk 1 — Regulatory and CMS policy risk (the defining risk). Humana’s revenue and profitability are set, in large part, by the federal government. CMS controls the annual Medicare Advantage rate notice, the risk-adjustment methodology, and the Star Ratings framework that determines quality bonuses. A single unfavorable policy cycle can compress margins across the entire industry, and Humana — as the most MA-concentrated large insurer — has the least ability to absorb such a shock through other business lines. The 2026 Star Ratings setback that forced the GAAP guidance cut to a minimum of $6.52 per share (from at least $8.36) is a live demonstration of how quickly a regulatory input can reprice earnings. Any future move to slow MA benchmark growth, tighten coding intensity adjustments, or restructure quality bonuses would strike directly at the recovery thesis. This risk cannot be diversified away within the business model; it can only be underwritten as the price of owning the purest MA franchise.
Risk 2 — Medical cost trend and utilization risk. The entire recovery depends on medical costs behaving roughly as priced. If senior utilization continues to run hotter than assumed — driven by elevated elective procedures, expensive specialty and GLP-1 drug adoption, or a sicker-than-expected mix of new enrollees — the MLR could remain stuck above 90% and margins would fail to recover on schedule. The Q2 2026 MLR of 91.1% and the observation that newer, higher-acuity members are pressuring the ratio show this risk is already partly realized. Pricing an insurance book is inherently a forecast, and if the forecast underestimates cost trend, the 2027 and 2028 repricing may prove insufficient, pushing the recovery out in time and compressing the present value of the thesis. Because margins on a $140-billion-plus revenue base are thin, even a modest miss on cost trend has an outsized earnings impact.
Risk 3 — Execution and concentration risk. The recovery is not automatic — it requires management to execute a multi-year plan: reprice 2027 bids correctly, exit unprofitable markets without triggering excessive membership loss, restore Star Ratings through operational quality improvements, and integrate acquisitions like MaxHealth into CenterWell profitably. Each step carries execution risk, and the company’s concentration in Medicare Advantage means there is little to offset a stumble. Market exits, in particular, are a double-edged sword: they improve margins but shrink the membership base and can damage relationships with brokers and members in affected regions. If Humana trims too aggressively, it sacrifices the volume growth that underpins long-term value; if it trims too little, margins recover more slowly. Threading that needle over three bid cycles, while a large, sophisticated peer set competes for the same seniors, is a real operational challenge that the trough valuation only partially discounts.
—
7. Conclusion & Exit Plan
Investment rating: Buy (recovery play, suitable for investors with a two-to-three-year horizon and tolerance for regulatory volatility).
Humana offers a well-defined, quantifiable recovery in a defensive, demographically underpinned industry, available at a price that pays for the base case and provides the bull case largely for free. The trailing P/E of 36x is a distraction; the forward P/E of 23x and the low-double-digit multiple on normalized 2028 earnings are the real valuation, and both point to a business trading below its through-cycle worth. The wave of analyst upgrades reflects growing institutional conviction that 2026 is the trough and that the 3% pretax MA margin target for 2028 is achievable. CenterWell provides a second, less cyclical growth engine that a pure insurance valuation underappreciates.
Entry price range. The current price of $384.48 is a reasonable entry for a full-conviction base-case buyer. For those seeking a wider margin of safety, accumulating in the $350–385 range improves the risk/reward, and any pullback toward the low-$300s on a regulatory scare — absent a genuine break in the 2028 math — would represent an attractive addition point given the $163 52-week low reflects a fear-driven bottom the fundamentals have since moved past.
Exit conditions:
– Target achieved: Trim into strength around the base-case fair value of $418–420 (consensus and our base case), and take further profits toward the bull-case $488 if the 2028 margin target is confirmed on track through the 2027 bid results.
– Fundamental break: Sell if the medical loss ratio fails to improve for two consecutive years and the 2028 pretax MA margin target of at least 3% is explicitly abandoned or pushed out, or if a CMS policy change structurally lowers MA payment generosity — either event breaks the recovery thesis.
– Time-based: Reassess the position after the 2027 Medicare Advantage bid results and Star Ratings for Bonus Year 2027 are known, as those will be the first hard evidence of whether the repricing is working. A formal review is warranted in roughly 12 months or upon the next Star Ratings release, whichever comes first.
Summary table:
Item Detail Company Humana Inc. (HUM) Current Price $384.48 Target Price $420 (base case) Upside ~9% (base) / ~27% (bull) Rating Buy Key Thesis Trough-earnings Medicare Advantage margin recovery toward a 3% pretax margin by 2028, plus CenterWell growth, mispriced by a distracting trailing P/E Main Risk CMS/Star Ratings regulatory policy compressing MA economics with no diversification to offset it
—
This article is for informational purposes only and does not constitute investment advice. All data sourced from public filings, analyst reports, and news as of the publication date. Invest at your own discretion.
This content is general investment information provided to an indefinite/unspecified audience by a quasi-investment advisory business registered under Korea’s Financial Investment Services and Capital Markets Act, and is not personalized 1:1 investment advice tailored to any individual investor. This analysis is for informational purposes only and is not a solicitation to invest. All investment decisions and their consequences rest solely with the investor. The estimates and assumptions in this report are as of the writing date (2026-08-14) and may not materialize depending on market conditions and geopolitical variables. Financial data used reflects sources such as company filings and analyst consensus, and the scenarios and price targets represent the author’s conservative assessment. All investments carry the risk of principal loss, and past performance or analytical track record does not guarantee future results. As of the writing date, the author does not hold a position in this stock. The author’s holdings and positions may change without prior notice depending on market conditions.
함께 읽으면 좋은 글
- Berkshire Hathaway Q2 2026 Buyback Reality Check [2026년 8월 재분석]: Why the $4.5B Repurchase and First Cash-Pile Decline in Years Reset the BRK.B Fair Value at $555
- Kratos Defense Hypersonics Ramp to $700 Million by 2027: Why a $2 Billion Backlog Makes KTOS the Defense Growth Story to Watch
- AppLovin AXON E-Commerce Advertising: Why the Post-Earnings Selloff Created a $464 Opportunity at 16x Forward Earnings
- [2026년 08월 재분석] Applied Materials AMAT 22% Pullback Into Q3 Earnings: Why the $700 Base Case Round-Tripped and Where the Risk/Reward Resets at $539
- Paycom Automation Margin Expansion Analysis: Why the Q2 2026 Guidance Raise to $1 Billion Adjusted EBITDA Signals a Re-Rating